
Seeking Projects Advancing Human-Animal Bond >
Event seeks innovative solutions for the well-being and care of companion animals and their pet parents.

PANOQUELL®-CA1 (fuzapladib sodium for injection) is now available in the U.S. >
The first and only drug conditionally approved by the FDA for management of the symptoms associated with acute onset of canine pancreatitis

WVA Global Veterinary Awards launched >
New awards recognize work in One Health, Animal Welfare, Medicine Stewardship and Veterinary Education

Ceva Launches Wildlife Research Fund >
Ceva Wildlife Research Fund, the first endowment fund dedicated to research to protect wildlife.

CEVA EXPANDS ORAL RABIES VACCINE PORTFOLIO WITH THE ACQUISITION OF CANADIAN FIRM ARTEMIS TECHNOLOGIES, INC. >
Libourne, May 16, 2022 – Ceva Santé Animale (Ceva) has acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc. Artemis, located in Guelph, ON, Canada, produces ONRAB®, a rabies glycoprotein recombinant oral vaccine licensed for use in striped skunks (Mephitis mephitis) in Canada. The product also had positive field trial use in the USA in wild raccoons and skunks. "Ceva’s...

Ceva Helps to Expand COVID-19 Testing >
MAWD Pathology increases same-day COVID-19 testing using equipment on loan from Ceva

Ceva Returns Strong Double-Digit Growth in 2019; Plans to Double sales by 2020. >
Consolidated sales of the Ceva Group reached more than €1.2 billion in 2019.

Program Receives Quality Recognition >
Ceva’s U.S. C.H.I.C.K Program receives independently audited quality recognition from Bureau Veritas

Ceva Sponsors Kitten Bowl VI to Shine Spotlight on Pet Adoption >
Ceva Animal Health is kicking off kitten adoption season as a marquis sponsor of Hallmark Channel’s upcoming Kitten Bowl VI, the newest installment of the nation’s most beloved feline faceoff, featuring adoptable cats and kittens. Past Kitten Bowl broadcasts have inspired more than 25,000 adoptions from animal shelter partners across the country. Kitten Bowl VI premieres Sunday, Feb. 3, 2019, and...

CEVA LAUNCHES FIRST FDA-APPROVED GENERIC OF MILBEMYCIN OXIME IN U.S. >
Ceva Animal Health has launched MilbeGuard™ (milbemycin oxime) Flavored Tablets, the first FDA-approved generic milbemycin oxime in the U.S. MilbeGuard is a monthly, beef-flavored tablet that prevents heartworm disease, and treats and controls whipworms (in dogs only), hookworms and roundworms. The active ingredient, milbemycin oxime, has been trusted by veterinarians to control heartworm for years....